KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Share-based Compensation (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Share-based Compensation for 8 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation changed 0.29% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.9 million through Dec 2025, down 8.8% year-over-year, with the annual reading at $45.9 million for FY2025, 8.8% down from the prior year.
  • Share-based Compensation hit $11.4 million in Q4 2025 for Castle Biosciences, down from $12.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q1 2023 to a low of $4.8 million in Q2 2021.
  • Historically, Share-based Compensation has averaged $10.3 million across 5 years, with a median of $11.3 million in 2025.
  • Biggest five-year swings in Share-based Compensation: soared 211.54% in 2021 and later decreased 14.96% in 2025.
  • Year by year, Share-based Compensation stood at $6.9 million in 2021, then soared by 44.84% to $9.9 million in 2022, then grew by 18.94% to $11.8 million in 2023, then fell by 3.08% to $11.4 million in 2024, then fell by 0.29% to $11.4 million in 2025.
  • Business Quant data shows Share-based Compensation for CSTL at $11.4 million in Q4 2025, $12.1 million in Q3 2025, and $11.2 million in Q2 2025.